Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
5 hedge funds and large institutions have $727K invested in Soleno Therapeutics in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
7.26% more ownership
Funds ownership: 0% → 7.26% (+7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bollard Group
Boston,
Massachusetts
|
+$945K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$330K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.85K |
Top Sellers
SLNO Hedge Fund Activity: Q4 2014 in Review
5 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2014, worth a combined $727K.
Buyers outnumbered sellers: 5 funds opened new SLNO positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bollard Group, opening a new position worth an estimated $945K.
- 5 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $727K of Soleno Therapeutics stock for Q4 2014.
- 5 funds opened new Soleno Therapeutics positions in Q4 2014 and 0 closed out, a net change of +5 holders.
- The largest Soleno Therapeutics buyer in Q4 2014 was Bollard Group, an estimated $945K added.
Based on aggregated 13F filings for Q4 2014.